CYTK.NASDAQCytokinetics INC

Form 4: Cytokinetics Executive Sells Shares

Sentiment:

Insider Transaction (Form 4)


Fady Ibraham Malik, EVP Research & Development of Cytokinetics Inc, sold 3,500 shares of common stock on July 21, 2026 for $80.59 per share.

Summary

  • Option exercise/conversion: acquired 3,500 Common Stock at $7.80 ($27,300) on July 21, 2026; holds 157,402 after (Direct).
  • Open-market sale: disposed of 3,500 Common Stock at $80.59 ($282,065) on July 21, 2026; holds 153,902 after (Direct).
  • Option exercise/conversion: disposed of 3,500 Non-Qualified Stock Option (Right to Buy) on July 21, 2026; holds 33,886 after (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $282,065 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

Fady Ibraham Malik — Officer (EVP Research & Development)

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-07-21Option exercise/conversionCommon Stock3,500$8$27.3K157,402
2026-07-21Open-market saleCommon Stock3,500$81$282.1K153,902
2026-07-21Option exercise/conversionNon-Qualified Stock Option (Right to Buy)3,500——33,886

Key Dates

DateDescription
2026-07-21Option exercise/conversion (3,500 shares)
2026-07-21Open-market sale (3,500 shares)
2026-07-21Option exercise/conversion (3,500 shares)

Keywords

insider transaction, Form 4, CYTK, CYTOKINETICS INC, bearish, Fady Ibraham Malik

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.